The stock's fall snapped an eight-day winning streak.

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...

It’s been called the closest the world has ever come to a vaccine against the AIDS virus. The twice-yearly shot was 100% ...

In October, lenacapavir manufacturer, Gilead, announced a deal that allows six manufacturers to produce generic versions of ...

Here is the chance for fans to vote for the favorite boys and girls bowlers to become the Marion Star Preseason Bowlers of ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...

We face a crucial decision as President-elect Trump’s team takes shape and begins to govern: whether to view other Americans ...

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new ...

Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects ...